Some studies reported that administration of SIRT1 activator ameliorated fat accumulation in the liver of monosodium glutamate (MSG) mice which exhibited obesity and IR, and the expression of lipogenic genes, such as SREBP-1c, FAS, and ACC, was reduced by SIRT1 activator treatment, with declined expression of inflammatory cytokines, which also provided evidence for the critical role of inflammation in hepatocytes lipogenesis [28, 29]. The gene discussed is SIRT1; the disease is obesity disorder.